Il­lu­mi­na and Deer­field link arms to dri­ve 'ge­nomics-first' drug dis­cov­ery

Af­ter years of part­ner­ing with the phar­ma in­dus­try, Il­lu­mi­na is now mak­ing its own for­ay in­to drug dis­cov­ery. The DNA se­quenc­ing com­pa­ny is en­ter­ing a 5-year col­lab­o­ra­tion with Deer­field Man­age­ment to use its ge­nom­ic tools and AI-dri­ven plat­form to iden­ti­fy new ther­a­peu­tic tar­gets and bend the curve on high fail­ure rates.

The inklings of the part­ner­ship be­gan in 2020 when Il­lu­mi­na bought Blue­Bee, a cloud com­put­ing com­pa­ny which was al­so in con­tract with Deer­field at the time, Matt Nel­son, VP of ge­net­ics and ge­nomics at Deer­field Dis­cov­ery and De­vel­op­ment, told End­points News.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER